Australia possesses a world-class reputation for medical research, boasting a healthcare system that is the envy of many developed nations. Yet, beneath this veneer of clinical excellence lies a systemic failure: the country is effectively starving its burgeoning women’s health (femtech) sector of the capital and support required to scale.
As female innovators gather at industry summits to sound the alarm, a concerning narrative has emerged. While Australian startups are pioneering life-changing technologies, a lack of local venture capital is forcing the country’s brightest minds to seek funding—and often, permanent relocation—offshore.
The State of the Sector: A Stark Reality
The numbers tell a sobering story. According to the State of Australian Startup Funding report, a mere 2% of all venture capital deployed into the Australian startup ecosystem in 2025 went to all-female-founded teams. This figure is not merely a statistical anomaly; it is a structural barrier that is stifling the "femtech" revolution.
At the recent Women’s Health and Wellbeing Summit in Sydney, the atmosphere was one of frustration tempered by determination. Founders, researchers, and venture capitalists convened to dissect why Australia, a nation that prides itself on egalitarian values and scientific rigor, remains a "venture desert" for women’s health technology.
The consensus among attendees was clear: investors are failing to prioritize health tech, particularly innovations addressing conditions that have been historically sidelined by the medical establishment. From reproductive health and menopause management to AI-driven diagnostics for pregnancy, the potential for market disruption is immense—but the capital pipelines remain dry.
The Case of Baymatob: A Symptom of a Broken System
Perhaps no one understands this friction better than Tara Croft, CEO of Baymatob. Her company is the developer of Oli, a sophisticated AI-powered sensor designed to improve safety outcomes during pregnancy and childbirth. It is exactly the kind of "moonshot" innovation that Australia claims to foster.
However, for Croft, the journey to commercialization has been, in her own words, "exceptionally difficult." Despite the clinical promise of her technology, the local investment landscape offered little in the way of sustained support.
"I’ve done three capital rounds predominantly in Australia, with 30% offshore capital, and the other half of my funding has been from government grants," Croft explained to the summit delegates. "Had we had stronger support from investors, we would have been in market two or three years ago."
Croft’s experience highlights a recurring theme: Australian founders are forced to become masters of "grant-chasing" rather than focusing on rapid scaling. By the time a founder has navigated the labyrinth of government bureaucracy to secure a grant, their international competitors—often backed by venture capital from the US or Europe—have already secured patents, cleared regulatory hurdles, and captured market share.
Chronology of a Crisis
To understand how Australia arrived at this impasse, one must look at the evolution of the local venture capital (VC) market over the last decade.
- 2015–2018: The Rise of Fintech and SaaS: The early growth of the Australian startup ecosystem was heavily skewed toward fintech, e-commerce, and software-as-a-service (SaaS). Investors sought low-risk, high-velocity returns. Health tech, which often requires longer "time-to-market" due to regulatory approvals and clinical trials, was deemed too risky.
- 2019–2021: The Pandemic Pivot: During the COVID-19 pandemic, interest in health technology surged globally. However, in Australia, the focus remained largely on telehealth and general health apps. Deep-tech femtech—which requires specialized biological and engineering expertise—remained underfunded.
- 2022–2024: The Funding Crunch: As global interest rates rose and the venture capital market tightened, Australian investors became increasingly conservative. Female founders, who already faced unconscious bias in pitch rooms, found themselves at the bottom of the priority list.
- 2025–Present: The "Brain Drain": The current cycle is defined by exodus. As founders like Croft struggle to bridge the "valley of death" between prototype and commercialization, they are increasingly looking to the US, the UK, and Singapore. These jurisdictions offer not only deeper pools of capital but also a more nuanced understanding of the health tech sector’s long-term value proposition.
Supporting Data: The Gendered Investment Gap
The 2% figure mentioned in the State of Australian Startup Funding report is not just a reflection of the "all-female founder" metric; it is emblematic of a broader, systemic bias. Even when female founders are part of mixed-gender teams, they often struggle to secure the same ticket sizes as their male counterparts.
Industry analysts point to three primary drivers of this disparity:
- Homogenous Investment Committees: The vast majority of Australian VC firms are led by men. Studies consistently show that investors are more likely to fund ventures that mirror their own life experiences, creating an inherent blind spot for women’s health issues.
- Risk Aversion regarding "Niche" Markets: Historically, medical issues unique to women were labeled as "niche." Investors failed to realize that women represent half the population and control the majority of household healthcare spending.
- Lack of Specialized Due Diligence: Assessing a health-tech startup requires a specialized skill set. Many Australian VC firms lack the in-house scientific expertise to properly evaluate the potential of deep-tech health innovations, leading them to reject proposals they simply do not understand.
Official Responses and the Push for Policy Reform
Government bodies and industry advocates are beginning to respond to the criticism, though many argue the response has been reactive rather than proactive.
The Australian Government has recently signaled an intent to increase funding for the medical research commercialization sector, with new grants under the Medical Research Future Fund (MRFF). However, critics argue that grants are not a substitute for the strategic partnership that venture capital provides.
"A grant pays the bills, but a VC partner provides the network, the governance, and the strategic guidance to take a company global," says one industry consultant who requested anonymity. "We are creating a nation of researchers who are excellent at winning grants but ill-equipped to build sustainable, multi-billion-dollar companies."
There is growing pressure on the Australian government to introduce tax incentives specifically for "impact investing" in women’s health. Furthermore, there are calls for the Australian Investment Council to implement mandatory diversity reporting for VC firms to track whether the capital they manage is being deployed equitably.
Implications: The Long-term Cost of Inaction
The implications of failing to support women’s health startups extend far beyond the balance sheets of a few companies.
1. The Loss of Intellectual Property: When Australian startups move offshore, they take their patents, their intellectual property, and their future tax revenue with them. Australia effectively subsidizes the research through grants, only to see the economic benefits harvested by foreign markets.
2. The Clinical Gap: If Australian innovation is stifled, the Australian healthcare system will eventually be forced to import expensive, foreign-developed technologies to treat its own population. This creates a cycle of dependency on international markets.
3. Talent Migration: The "brain drain" is not just about companies; it is about people. When female scientists and engineers see that their peers are failing to secure funding in Australia, they move to ecosystems where their work is valued. This creates a long-term deficit in local expertise, further weakening the nation’s ability to compete in the global biotech race.
The Path Forward: What Needs to Change?
The narrative around women’s health in Australia is at a crossroads. To reverse the current trend, a multi-stakeholder approach is required:
- For Investors: There must be a concerted effort to diversify investment committees. Bringing more women into decision-making roles is not just a matter of social equity; it is a financial imperative to identify overlooked market opportunities.
- For Founders: There is a need for better support networks that facilitate peer-to-peer mentoring and provide founders with the skills to navigate the global, rather than just the local, capital market.
- For Policy Makers: The focus must shift from "funding the research" to "funding the enterprise." Creating a robust commercialization framework that supports startups through the regulatory and clinical trial phases is essential.
As Tara Croft and her peers continue to fight for their place in the sun, the message to the Australian investment community is clear: women’s health is not a "niche" sector—it is a massive, untapped frontier. Australia can either choose to be the home of this innovation, or it can continue to watch from the sidelines as the rest of the world profits from its brilliance.
The time to bridge the gap is now. If Australia continues to starve its women’s health startups of the capital they deserve, it will not just be losing money—it will be losing the future of medicine itself.
